Nurix Therapeutics NRIX
NASDAQ NRIX
$26.14 +0.82 (+3.24%)
At close: Sep 4, 2026 · 4:00 PM EDT

Nurix Therapeutics (NRIX) Net Equity Issued and Repurchased (2020 - 2026)

Nurix Therapeutics (NRIX) posted quarterly Net Equity Issued and Repurchased of $18.0 million for Q1 2026, down 81.13% quarter-over-quarter from $95.4 million in Q4 2024.

Analysis

Nurix Therapeutics (NRIX) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends

Nurix Therapeutics (NRIX) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $18.0 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $18.0 million; the TTM figure through May 2026 stood at $18.0 million (down 86.98% YoY), while the FY2024 annual figure was $289.8 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased slipped to $18.0 million in Q1 2026 per NRIX's latest filing, from $95.4 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $95.4 million in Q4 2024 and bottomed at $18.0 million in Q1 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 141.90 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Nurix Therapeutics 2.90 Bn 2.46 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Feb 28, 2026 18.00 Mn
Nov 30, 2024 95.40 Mn
Aug 31, 2024 42.90 Mn
May 31, 2024 50.20 Mn
May 31, 2021 -43,000.00
Nov 30, 2020 -1.15 Mn
Aug 31, 2020 99.39 Mn
May 31, 2020 14,000.00